Biotech

Viking Therapeutics, Inc.

1

Articles

Competitor

Top Role

Jan 27, 2026

First Mention

Jan 27, 2026

Last Mention

0.61

Relevance Score

Coverage Timeline

January 2026

Obesity Pipeline Beyond GLP‑1s: Orforglipron, Survodutide, and the Oral Disruptors Pipeline Competitor

Jan 27, 2026

Structure and Viking’s oral agents remain in Phase 2, boasting promising double-digit weight loss.